Nandini Koneru
Nandini Koneru has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed S. Ibrahim
Department of Ophthalmology, Visual and Anatomical Sciences, School of Medicine, Wayne State University, Detroit, MI 48201, USA
1 shared publication - Gieth Alahdab
Eye Research Center, Oakland University William Beaumont School of Medicine (OUWB-SOM), Rochester, MI 48309, USA
1 shared publication - Krishna Rao Maddipati
Department of Pathology, Lipidomic Core Facility, Wayne State University, Detroit, MI, USA
1 shared publication - Michael L. Risner
William Beaumont School of Medicine, Department of Foundational Medical Studies, Oakland University, Eye Research Center, Rochester, USA
1 shared publication - Min Young Kim
Department of Ophthalmology, Hamilton Eye Institute, The University of Tennessee Health Science Center, Memphis, TN 38163, USA
1 shared publication - Mohamed Al-Shabrawey
Eye Research Center, Oakland University William Beomaunt School of Medicine , Rochester, USA; Eye Research Institute, Oakland University, Rochester, USA; Foundational Medical Studies, Oakland University William Beaumont School of Medicine, Rochester, USA, USA
1 shared publication
Latest Publications
- Open Access
- 14 October 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (10) , 1450
Alterations of Bioactive Lipid Profiles in the Retina Following Traumatic Optic Neuropathy in Mice
Traumatic optic neuropathy (TON) causes vision loss through compression and contusion, yet there is no consensus on the most effective treatment. Polyunsaturated fatty acid (PUFA)-derived bioactive lipids metabolized by lipoxygenase (LOX), cytochrome P450 (CYP), and cyclooxygenase (COX) enzymes are known mediators of inflammation and neurodegeneration. However, their role in TON-related retinal pathology remains unclear. Controlled orbital impact (COI) was used to induce unilateral TON in mice with controlled velocity (2–3 m/s), with the fellow eye serving as an internal control. Retina tissues were collected three days post-injury and analyzed by LC/MS to quantify bioactive lipid metabolites from ω−6 and ω−3 PUFAs. Statistical analysis was performed using paired, nonparametric Wilcoxon signed-rank tests with Benjamini–Hochberg false discovery rate (FDR) correction. Results showed that among 38 reliably detected metabolites, no individual lipid showed a statistically significant difference between TON and control eyes after FDR correction (q < 0.05). However, both individual and pathway-level analysis revealed consistent trends toward increased expression of LOX- and CYP-derived metabolites across FDA PUFA substrates, including arachidonic acid (AA), linoleic acid (LA), and docosahexaenoic acid (DHA). These findings support further investigation into lipid-mediated inflammation in TON and its potential as a therapeutic target, particularly through expanding both the sample size and the post-TON time periods.
- 14 October 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (10) , 1450
Open AccessAlterations of Bioactive Lipid Profiles in the Retina Following Traumatic Optic Neuropathy in Mice
Traumatic optic neuropathy (TON) causes vision loss through compression and contusion, yet there is no consensus on the most effective treatment. Polyunsaturated fatty acid (PUFA)-derived bioactive lipids metabolized by lipoxygenase (LOX), cytochrome P450 (CYP), and cyclooxygenase (COX) enzymes are known mediators of inflammation and neurodegeneration. However, their role in TON-related retinal pathology remains unclear. Controlled orbital impact (COI) was used to induce unilateral TON in mice with controlled velocity (2–3 m/s), with the fellow eye serving as an internal control. Retina tissues were collected three days post-injury and analyzed by LC/MS to quantify bioactive lipid metabolites from ω−6 and ω−3 PUFAs. Statistical analysis was performed using paired, nonparametric Wilcoxon signed-rank tests with Benjamini–Hochberg false discovery rate (FDR) correction. Results showed that among 38 reliably detected metabolites, no individual lipid showed a statistically significant difference between TON and control eyes after FDR correction (q < 0.05). However, both individual and pathway-level analysis revealed consistent trends toward increased expression of LOX- and CYP-derived metabolites across FDA PUFA substrates, including arachidonic acid (AA), linoleic acid (LA), and docosahexaenoic acid (DHA). These findings support further investigation into lipid-mediated inflammation in TON and its potential as a therapeutic target, particularly through expanding both the sample size and the post-TON time periods.